Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
Kidney International Reports
|
June 15, 2026
Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status
Ricardo Correa-Rotter, Peter Rossing, Maria Eugenia Canziani, et al.
Diabetes, Obesity & Metabolism
|
April 28, 2021
Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials
Annemarie B van der Aart-van der Beek, David Cherney, Gozewijn D Laverman, et al.
Diabetes, Obesity & Metabolism
|
July 26, 2024
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
Katina Zheng, Amirhossein Azhie, Xiaoting You, et al.
Circulation. Heart Failure
|
July 2, 2026
Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy
Jeffrey M Testani, Daniel P Judge, Barry A Borlaug, et al.
Lancet (London, England)
|
December 18, 2023
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
Katherine R Tuttle, Sibylle J Hauske, Maria Eugenia Canziani, et al.
Kidney International
|
September 24, 2021
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
Hiddo J L Heerspink, David Cherney, Douwe Postmus, et al.
JACC. Heart Failure
|
June 15, 2024
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics
Mikhail N Kosiborod, David Cherney, Kim Connelly, et al.
Journal of the American College of Cardiology
|
October 27, 2022
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria
Ashish Sarraju, George Bakris, Christopher P Cannon, et al.
Pediatric Diabetes
|
August 26, 2021
Tubular injury in diabetic ketoacidosis: Results from the diabetic kidney alarm study
Federica Piani, Isabella Melena, Cameron Severn, et al.
Diabetes & Vascular Disease Research
|
October 20, 2022
Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis
Elisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
Kidney International Reports
|
June 15, 2026
Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status
Ricardo Correa-Rotter, Peter Rossing, Maria Eugenia Canziani, et al.
Diabetes, Obesity & Metabolism
|
April 28, 2021
Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials
Annemarie B van der Aart-van der Beek, David Cherney, Gozewijn D Laverman, et al.
Diabetes, Obesity & Metabolism
|
July 26, 2024
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
Katina Zheng, Amirhossein Azhie, Xiaoting You, et al.
Circulation. Heart Failure
|
July 2, 2026
Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy
Jeffrey M Testani, Daniel P Judge, Barry A Borlaug, et al.
Lancet (London, England)
|
December 18, 2023
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
Katherine R Tuttle, Sibylle J Hauske, Maria Eugenia Canziani, et al.
Kidney International
|
September 24, 2021
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
Hiddo J L Heerspink, David Cherney, Douwe Postmus, et al.
JACC. Heart Failure
|
June 15, 2024
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics
Mikhail N Kosiborod, David Cherney, Kim Connelly, et al.
Journal of the American College of Cardiology
|
October 27, 2022
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria
Ashish Sarraju, George Bakris, Christopher P Cannon, et al.
Pediatric Diabetes
|
August 26, 2021
Tubular injury in diabetic ketoacidosis: Results from the diabetic kidney alarm study
Federica Piani, Isabella Melena, Cameron Severn, et al.
Diabetes & Vascular Disease Research
|
October 20, 2022
Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis
Elisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, et al.
Page
of 6